Richard E Olson
Overview
Explore the profile of Richard E Olson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
556
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Easton A, Jensen M, Wang C, Hagedorn P, Li Y, Weed M, et al.
Mol Ther Nucleic Acids
. 2022 Sep;
29:625-642.
PMID: 36090761
Tau is a microtubule-associated protein (, tau) implicated in the pathogenesis of tauopathies, a spectrum of neurodegenerative disorders characterized by accumulation of hyperphosphorylated, aggregated tau. Because tau pathology can be...
2.
Hagedorn P, Brown J, Easton A, Pierdomenico M, Jones K, Olson R, et al.
Nucleic Acid Ther
. 2022 Feb;
32(3):151-162.
PMID: 35166597
Antisense oligonucleotides are a relatively new therapeutic modality and safety evaluation is still a developing area of research. We have observed that some oligonucleotides can produce acute, nonhybridization dependent, neurobehavioral...
3.
Huang Y, Knouse K, Qiu S, Hao W, Padial N, Vantourout J, et al.
Science
. 2021 Sep;
373(6560):1265-1270.
PMID: 34516793
The promise of gene-based therapies is being realized at an accelerated pace, with more than 155 active clinical trials and multiple U.S. Food and Drug Administration approvals for therapeutic oligonucleotides,...
4.
Zhang Y, Boy K, Wu Y, Ramirez A, Toyn J, Ahlijanian M, et al.
Bioorg Med Chem Lett
. 2020 Sep;
30(22):127530.
PMID: 32890687
In an effort to improve physical properties by introducing polar functionality into the bicyclic pyrimidine gamma-secretase modulator (GSM) clinical candidate BMS-932481, we prepared several oxidative products of BMS-932481. Among the...
5.
Anderson B, Jensen M, Hagedorn P, Little S, Olson R, Ammar R, et al.
Mol Ther Nucleic Acids
. 2020 Feb;
19:1290-1298.
PMID: 32092825
Hundreds of dominant-negative myosin mutations have been identified that lead to hypertrophic cardiomyopathy, and the biomechanical link between mutation and disease is heterogeneous across this patient population. To increase the...
6.
Guarino V, Olson R, Everlof J, Wang N, Mcdonald I, Haskell R, et al.
Bioorg Med Chem Lett
. 2019 Dec;
30(3):126856.
PMID: 31870650
The objective of this Letter is to report the first (to our knowledge) in vivo proof of concept for a sulfenamide prodrug to orally deliver a poorly soluble drug containing...
7.
Boy K, Guernon J, Zuev D, Xu L, Zhang Y, Shi J, et al.
ACS Med Chem Lett
. 2019 Mar;
10(3):312-317.
PMID: 30891132
A triazine hit identified from a screen of the BMS compound collection was optimized for potency, in vivo activity, and off-target profile to produce the bicyclic pyrimidine γ-secretase modulator BMS-932481....
8.
Knouse K, deGruyter J, Schmidt M, Zheng B, Vantourout J, Kingston C, et al.
Science
. 2018 Aug;
361(6408):1234-1238.
PMID: 30072577
Phosphorothioate nucleotides have emerged as powerful pharmacological substitutes of their native phosphodiester analogs with important translational applications in antisense oligonucleotide (ASO) therapeutics and cyclic dinucleotide (CDN) synthesis. Stereocontrolled installation of...
9.
Marcin L, Warrier J, Thangathirupathy S, Shi J, Karageorge G, Pearce B, et al.
ACS Med Chem Lett
. 2018 May;
9(5):472-477.
PMID: 29795762
There is a significant unmet medical need for more efficacious and rapidly acting antidepressants. Toward this end, negative allosteric modulators of the -methyl-d-aspartate receptor subtype GluN2B have demonstrated encouraging therapeutic...
10.
Cook J, Zusi F, Hill M, Fang H, Pearce B, Park H, et al.
Bioorg Med Chem Lett
. 2017 Oct;
27(22):5002-5005.
PMID: 29050783
We describe an efficient and convergent synthesis of a series of (1'S,2R,4'S)-3H-4'-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2'-bicyclo[2.2.2]octanes] displaying potency for the α7 nicotinic acetylcholine receptor (nAChR) and good selectivity vs. the related 5-HT receptor.